Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for May 18, 2021

5/18/2021

 
Regulatory Update
 
The FDA approved pegcetacoplan (Empaveli, Apellis Pharmaceuticals), on 5/14/2021, for the treatment of paroxysmal nocturnal hemoglobinuria in both treatment naïve patients and patients switching from eculizumab or ravulizumab. Pegcetacoplan was approved with a Black Box warning regarding the increased risk of meningococcal and other serious infections caused by encapsulated bacteria that may become rapidly life threatening or fatal if not recognized and treated early. A Risk Evaluation and Mitigation Strategy (REMS) program requires prescribers to counsel patients on the risk of serious infection, provide patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria.
 
The FDA approved an extended-release, locally administered solution of bupivacaine and meloxicam (Zynrelef, Heron Therapeutics), on 5/13/2021, for postsurgical analgesia after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.
 
The FDA accepted the NDA for levoketoconazole, for the treatment of endogenous Cushing’s syndrome and set a PDUFA date for 1/1/2022.
 
The FDA granted losmapimod Fast Track status for the treatment of facioscapulohumeral muscular dystrophy.
 
Announced Research Updates
 
Biogen announced that in the 12-month, 50 patient, Phase II/III XIRIUS trial, treatment with cotoretigene toliparvovec did not improve Macular Integrity Assessment (MAIA) Microperimetry compared to an untreated group of male patients with X-linked retinitis pigmentosa.
 
Published Research Updates
 
In a 196 patient, Japanese study, elobixibat was similar to sodium picosulfate  when either drug was added to 1 L of polyethylene glycol formulation containing ascorbic acid as a bowell cleaning preparation for colonoscopy as evidenced by similar Boston Bowel Preparation Scale scores (8.3 vs 8.3). 
 
In the 392 patient, Phase III AHELP trial, treatment with apatinib resulted in overall survival of 8.7 months compared to 6.8 months with placebo in Chinese patients with pretreated advanced hepatocellular carcinoma.
 
In the 52-week, 1,061 patient, Phase III NAVIGATOR trial, the annualized asthma exacerbation rate with tezepelumab was 0.93 compared to 2.1 with placebo in patients 12 to 80 with severe uncontrolled asthma. 
 
In the 16-week, 440 patient, Phase III, BREEZE-AD5 trial, 30% of patients treated with baricitinib 2 mg achieved EASI-75 compared to 8% with placebo in patients with moderate to severe atopic dermatitis. Improvement with a 1 mg dose of baricitinib did not reach significance.
 
In a draft review of JAK inhibits for the treatment of atopic dermatitis, ICER estimated the annual cost of abrocitinib at $37,500 to be cost-effective at $150,000 per QALY. ICER found insufficient evidence to compare abrocitinib to dupilumab. ICER also found that abrocitinib may improve severity, itch and sleep compared to topical therapies. The evidence is considered insufficient to compare abrocitinib, upadacitinib, baricitinib and tralokinumab.
 
In a draft review of JAK inhibits for the treatment of atopic dermatitis, ICER estimated the annual cost of tralokinumab at $31,500 to be cost-effective at $150,000 per QALY. Based on available evidence ICER found the evidence for tralokinumab to be comparable or inferior to dupilumab. ICER also found that tralokinumab may improve severity, itch and sleep compared to topical therapies. Based on indirect evidence, abrocitinib and upadacitinib appear to have more favorable outcomes than baricitinib or tralokinumab.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.